Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
After the company reported second-quarter results and cut guidance, shares of ViewRay (VRAY +0.00%), a medical equipment company that sells the MRIdian Linac system, fell 56% as of 1:37 p.m. EDT on Friday.
Just how bad was the news?
Management also poured cold water on its full-year guidance:
Between the disappointing orders, declining backlog, surprise CFO departure, and guidance cut, it's no wonder shares are being cut in half today.
CEO Scott Drake stated: "We are disappointed to take down guidance for the year, but we believe it is prudent given the timing of installations around year-end. We remain focused on the long-term opportunity versus short-term variability, and are confident that we will demonstrate the momentum of our growing pipeline and end-user demand moving forward."
Drake might be right about the long-term potential of the MRIdian cancer-treatment system, but the second-quarter results don't exactly inspire confidence in this company's ability to execute. That's troubling since it is still years away from reaching profitability.
If ViewRay can get its sales engine back on track, then the stock might be a tremendous bargain today. But this is a super-high-risk stock, so I plan to root for the company from the sidelines.